Hemopexin, Low Endotoxin Level, CAS 9013-71-2

Hemopexin, Low Endotoxin Level, CAS 9013-71-2
SKU
ATH16-16-080513-LEL-1
Packaging Unit
1 mg
Manufacturer
Athens Research & Technology

Availability: loading...
Price is loading...
Protein Catagory: Transport/other Proteins

Typ: Human

CAS Number: 9013-71-2

Molecular Weight: 57,000 Da

Immunogen: No

Compound Purity: ≥ 95% by SDS-Page

Applications: Cell Based Assays, Animal Studies, In Vitro Diagnostic, Glycosylation, Oxidative Damage, Lung Injury, Infection, Inflammation, Neurogenesis, Kidney Injury, Stroke, β-thalassemia, Sickle Cell Anemia, Epilepsy

References: - Aggarwal, S., et al., (2020), 'Reactive species generated by heme impair alveolar epithelial sodium channel function in acute respiratory distress syndrome', Redox Biology 36: pp 101592. Available at: https://doi.org/10.1016/j.redox.2020.101592 - Aggarwal, S., et al., (2018), 'Heme scavenging reduces pulmonary endoplasmic reticulum stress, fibrosis, and emphysema', JCI Insight., 3(21): pp e120694. Available at: https://doi.org/10.1172/jci.insight.120694

Product Description: Hemopexin is a plasma glycoprotein with the highest known binding affinity for free heme, functioning as a critical scavenger during intravascular hemolysis or cellular injury. Structurally, it comprises two β-propeller domains that form a high-affinity heme-binding pocket, enabling it to neutralize heme's oxidative toxicity and facilitate its transport to the liver for iron recycling via CD163 receptors. As an acute-phase reactant, hemopexin synthesis increases during inflammation, though chronic hemolysis often depletes its levels, exacerbating tissue damage. Deficiencies or dysfunction in hemopexin are implicated in hemolytic anemias such as sickle cell disease and β-thalassemia, where unbound heme drives endothelial activation, vaso-occlusion, and organ damage. It also correlates with neurologic complications in familial epilepsy due to impaired heme clearance in neural tissues and contributes to sepsis-related mortality by failing to counteract hemoglobin-mediated inflammation. Therapeutically, hemopexin supplementation shows promise in preclinical models, reducing cardiovascular dysfunction in sickle cell mice by 50% and mitigating renal injury in hemolysis. It serves as both a biomarker for hemolytic severity and a potential therapeutic agent to attenuate heme toxicity in transfusion medicine, atherosclerosis, and acute porphyrias.
More Information
SKU ATH16-16-080513-LEL-1
Manufacturer Athens Research & Technology
Manufacturer SKU 16-16-080513-LEL-1
Package Unit 1 mg
Quantity Unit STK
Product information (PDF) Download
MSDS (PDF) Download